Caron Bénédicte, Seksik Philippe, Buisson Anthony, Wils Pauline, Savoye Guillaume, Stefanescu Carmen, Laharie David, Guillo Lucas, Abitbol Vered, Bonnet Joelle, Altwegg Romain, Vuitton Lucine, Moussata Driffa, Bourreille Arnaud, Biron Amélie, Gilletta Cyrielle, Fumery Mathurin, Nahon Stephane, Nancey Stephane, Camara Houda, Peyrin-Biroulet Laurent
Department of Gastroenterology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.
Inserm, NGERE, University of Lorraine, Nancy, France.
Therap Adv Gastroenterol. 2024 Aug 7;17:17562848241265776. doi: 10.1177/17562848241265776. eCollection 2024.
Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown.
This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator.
In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale.
The differences in responses were performed using a one-way analysis of variance followed by Tukey's honest significant difference test.
The most commonly used drugs at inclusion were Humira (436/941, 46.3%), Amgevita (177/941, 18.8%) and Hulio (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) ( < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) ( < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects.
In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.
目前有几种阿达木单抗制剂可供炎症性肠病（IBD）患者使用。比较满意度和耐受性尚不清楚。
本研究调查了IBD患者对已批准的阿达木单抗生物类似药及其原研药的满意度。
在这项横断面研究中，我们纳入了45个隶属于消化管炎性疾病治疗研究组的中心连续接受阿达木单抗治疗的941例IBD患者，这些患者完成了一份包含四个项目的满意度问卷，每个项目采用10分制评分。
采用单因素方差分析及Tukey真实显著性差异检验进行反应差异分析。
纳入时最常用的药物为修美乐（436/941，46.3%）、安进（177/941，18.8%）和辉立达（105/941，11.2%）。阿达木单抗的总体平均满意度为8.5（标准差1.8）。接受修美乐（8.6（1.5））、辉立达（8.6（1.8））或安进（8.5（1.4））治疗的患者总体满意度显著更高（<0.05）。接受优时比（9.0（1.4））、修美乐（8.9（1.3））和辉立达（8.9（1.7））治疗的患者对皮下注射剂型的满意度更高（<0.05）。共有299例患者（31.8%）描述了注射部位反应。总共223例患者（23.7%）报告曾接受过另一种阿达木单抗治疗，其中32例（32/223，14.3%）因副作用停药。
在这种现实环境中，IBD患者对阿达木单抗治疗的满意度较高，在总体满意度和对注射装置的满意度方面存在一些差异。
